Bavarian Nordic A/S (OTCMKTS:BVNRY) Upgraded to “Hold” by Zacks Investment Research

Bavarian Nordic A/S (OTCMKTS:BVNRYGet Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Wednesday, reports.

According to Zacks, “Bavarian Nordic A/S is a biotechnology company. It focused on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases. The company’s product pipeline consists of IMVAMUNE(R), PROSTVAC (R), MVA-BN Brachyury, CV-301, MVA-BN Filo which are in clinical trial stage. Bavarian Nordic A/S is headquartered in Kvistgaard, Denmark. “

Several other equities research analysts have also issued reports on BVNRY. Cowen lowered shares of Bavarian Nordic A/S from an “outperform” rating to a “market perform” rating in a report on Friday, February 4th. UBS Group downgraded shares of Bavarian Nordic A/S from a “buy” rating to a “neutral” rating in a research report on Wednesday, December 22nd.

Shares of OTCMKTS:BVNRY traded down $0.25 during midday trading on Wednesday, reaching $7.41. 1,000 shares of the company were exchanged, compared to its average volume of 755. The business’s fifty day moving average is $9.01 and its two-hundred day moving average is $12.64. Bavarian Nordic A/S has a one year low of $7.33 and a one year high of $19.25.

Bavarian Nordic A/S (OTCMKTS:BVNRYGet Rating) last released its quarterly earnings data on Friday, March 4th. The company reported ($0.08) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.05) by ($0.03). The business had revenue of $83.65 million for the quarter, compared to analyst estimates of $93.33 million. As a group, research analysts predict that Bavarian Nordic A/S will post -1.03 earnings per share for the current year.

About Bavarian Nordic A/S (Get Rating)

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name.

Featured Articles

Get a free copy of the Zacks research report on Bavarian Nordic A/S (BVNRY)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Bavarian Nordic A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bavarian Nordic A/S and related companies with's FREE daily email newsletter.